Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 11, Pages 2726-2734
Publisher
Wiley
Online
2013-11-09
DOI
10.1002/ijc.28595
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quantitative Immunohistochemistry for Evaluating the Distribution of Ki67 and Other Biomarkers in Tumor Sections and Use of the Method to Study Repopulation in Xenografts after Treatment with Paclitaxel
- (2015) Andrea S. Fung et al. NEOPLASIA
- Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors
- (2013) J. K. Saggar et al. MOLECULAR CANCER THERAPEUTICS
- TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
- (2012) Qian Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer
- (2012) M. J. Borad et al. CANCER RESEARCH
- Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain
- (2012) Bin Yu et al. Scientific Reports
- Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
- (2011) J. D. Sun et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
- (2011) Kristen N. Ganjoo et al. ONCOLOGY
- Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
- (2010) J. Hu et al. BLOOD
- Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
- (2009) Krupa J Patel et al. BMC CANCER
- The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone
- (2009) O. Tredan et al. CANCER RESEARCH
- Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway
- (2009) S Inoue et al. CELL DEATH AND DIFFERENTIATION
- Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
- (2009) A. S. Fung et al. CLINICAL CANCER RESEARCH
- Tirapazamine: a novel agent targeting hypoxic tumor cells
- (2008) Srini B Reddy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started